Cuffed Versus Uncuffed Tracheal Tubes in PICU (PICU-BG-TT Study)
NCT ID: NCT03129893
Last Updated: 2023-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
242 participants
OBSERVATIONAL
2017-01-01
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The new CDC definition is used to identify patients with VAC and IVAC. The new definitions includes all associated complications (infection included) related to mechanical ventilation and exclude X-ray criteria.
VAP, VAT, VAC, IVAC rate, expressed as the number of VAP/VAT/VAC/IVAC episodes per 1000 mechanical ventilator days (VAP/1000 MV days), were calculated for phase 1 and phase 2.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cuff Pressure Regulation Apparatus for Tracheal Intubation in Children
NCT04413318
Continuous Control of Polyurethane Tracheal-cuff Pressure: Efficiency of a Pneumatic Device
NCT01351259
Continuous Control of Tracheal Cuff Pressure and Microaspiration in Critically Ill Patients
NCT01082666
Endotracheal Tube Cuff Pressure Measurement
NCT04397952
Ventilator Associated Pneumonia and Late Complications of Percutaneous Tracheostomy
NCT00184925
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The new CDC definition is used to identify patients with VAC and IVAC. The new definitions includes all associated complications (infection included) related to mechanical ventilation and exclude X-ray criteria.
VAP, VAT, VAC, IVAC rate, expressed as the number of VAP/VAT/VAC/IVAC episodes per 1000 mechanical ventilator days (VAP/1000 MV days), were calculated for phase 1 and phase 2.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients intubated with uncuffed tracheal tubes
Portex uncuffed TT sizes selected according to local institutional guidelines. Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to institutional guidelines in uncuffed TTs.
No interventions assigned to this group
Patients intubated with cuffed tracheal tubes
Cuffed TT sizes selected as follows: ID 3.0 mm for birth (\>3 kg body weight) to \< 8 months; ID 3.5 mm for 8 to \< 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
Cuffed tracheal tubes
Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cuffed tracheal tubes
Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Expected to require ventilation for \> 24 hours;
* Age: 0 - 5 year.
Exclusion Criteria
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mirco Nacoti, MD
Role: PRINCIPAL_INVESTIGATOR
ASST Papa Giovanni XXIII di Bergamo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric intensive care unit - ASST Papa Giovanni XXIII
Bergamo, BG, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PICU-BG-TT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.